论文部分内容阅读
本文作者观察了Fludarabine(FDB)(一种新的腺嘌呤核苷酸类似物)治疗幼稚淋巴细胞白血病(PLL)和慢性淋巴细胞白血病幼稚变(CLL-Pro)的效果。本组病人17例,男11例,女6例;年龄48～86岁,平均64岁。临床诊断根据病史、临床症状、体征(如脾严重肿大)和实验室检查(如诊断PLL要求骨髓中幼稚淋巴细胞≥30％,CLL-Pro骨髓中的幼稚淋巴细胞在10～29％之间),而最后确诊。本文17例,12例单用FDB,按30mg/m~2/日计,一次超过30分钟,连续5天/4周;另5例增用强的松,按60mg/m~2/日计,连续用5天。绝大多数(15例)治疗2个疗程,治疗无效的平均治疗时间3个月。17例的临床疗效为:3例完全缓解(18％),3例部分缓解
The authors observed the efficacy of Fludarabine (FDB), a novel adenine nucleotide analogue, for the treatment of immature lymphocytic leukemia (PLL) and chronic lymphocytic leukemia (CLL-Pro). The group of patients in 17 cases, 11 males and 6 females; aged 48 to 86 years, mean 64 years. Clinical diagnosis is based on medical history, clinical signs, signs (eg, severe splenomegaly), and laboratory tests (eg, diagnosing PLL requires ≥30% naïve lymphocytes in bone marrow and between 10-29% naïve lymphocytes in CLL-Pro bone marrow ), And finally confirmed. This article 17 cases, 12 cases of FDB alone, according to 30mg / m ~ 2 / day, more than 30 minutes for 5 consecutive days / 4 weeks; the other 5 cases with prednisone, according to 60mg / m ~ 2 / , For 5 consecutive days. The vast majority (15 cases) of two courses of treatment, the average treatment of ineffective treatment for 3 months. The clinical efficacy of 17 cases: 3 cases of complete remission (18%), 3 cases of partial remission